Please login to the form below

Not currently logged in
Email:
Password:

National Cancer Institute

This page shows the latest National Cancer Institute news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

At the time, lead investigator James Kochenderfer from the Center for Cancer Research at the National Cancer Institute in Bethesda said: “We have patients who have a sustained response and have ... and a $1.1bn agreement to acquire Impact Biomedicines

Latest news

  • Merck and Pfizer claim second FDA nod for cancer drug Bavencio Merck and Pfizer claim second FDA nod for cancer drug Bavencio

    first approval as a treatment for the skin cancer Merkel cell carcinoma (MCC). ... Commenting on the new approval, Andrea Apolo, an oncologist at National Cancer Institute in the US, said: "Once UC progresses after treatment with chemotherapy, the

  • FDA OK for Stivarga ends decade-long drought in liver cancer FDA OK for Stivarga ends decade-long drought in liver cancer

    FDA OK for Stivarga ends decade-long drought in liver cancer. Bayer's medicine wins US approval to treat hepatocellular carcinoma. ... According to the National Cancer Institute (NCI), more than 40, 000 people will be diagnosed with liver cancer in 2017

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    These account for around a third of the 50 subtypes of this form of cancer, which develops in muscles, fat, tendons or other soft tissues such as blood vessels. ... It was cleared as a second-line therapy after doxorubicin. The National Cancer Institute

  • Celgene bolsters blood cancer portfolio with $600m EngMab buy Celgene bolsters blood cancer portfolio with $600m EngMab buy

    Celgene bolsters blood cancer portfolio with $600m EngMab buy. Consolidates position as top company in current multiple myeloma market. ... BCMA-targeting drugs are also being developed by GlaxoSmithKline and Amgen, both of which have candidates in phase

  • Celgene takes aim at cancer innovation with new US research consortium Celgene takes aim at cancer innovation with new US research consortium

    The company will collaborate with four National Cancer Institute centres in the US over the next ten years to hasten the delivery of disease-altering programmes. ... Johns Hopkins; and The Tisch Cancer Institute at the Icahn School of Medicine at Mount

More from news
Approximately 2 fully matching, plus 81 partially matching documents found.

Latest Intelligence

  • An effective commercial model for cancer care An effective commercial model for cancer care

    Treatments for cancer are among the most expensive of all, regardless of disease. ... In an online survey of 8, 411 cancer patients administered by LIVESTRONG (the Lance Armstrong Foundation) and the National Cancer Institute's Health Information

  • EATRIS and the new age of partnering EATRIS and the new age of partnering

    In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... In October the National Cancer Institute will meet with specialists -

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    According to the US National Cancer Institute, about 12 per cent of women in the general population will develop breast cancer sometime during their lives. ... lung cancer, which was backed together with Roche Diagnostics' cobas EGFR Mutation Test.

  • Country report: The healthcare market in France Country report: The healthcare market in France

    National Cancer Institute (NCI) or the National Institute for Prevention and Education for Health (NIPEH). ... This applies to oncology drugs under France's national cancer care plan that includes fast access to new therapies.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • ASCO 2015: What you missed in Chicago

    Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Personalised treatments: targeting genetic mutations to treat cancer. The second area that really impressed me was the large National Cancer

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics